Amarin Corporation plc, each representing one Ordinary Share (AMRN): Price and Financial Metrics
Amarin Corporation plc, each representing one Ordinary Share (AMRN)
Today's Latest Price: $4.60 USD
Updated Nov 27 1:00pm
Add AMRN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
AMRN Stock Summary
- The price/operating cash flow metric for Amarin Corp Plc is higher than 98.23% of stocks in our set with a positive cash flow.
- For AMRN, its debt to operating expenses ratio is greater than that reported by just 7.37% of US equities we're observing.
- With a year-over-year growth in debt of -73.05%, Amarin Corp Plc's debt growth rate surpasses only 3.58% of about US stocks.
- Stocks that are quantitatively similar to AMRN, based on their financial statements, market capitalization, and price volatility, are EVER, HAYN, TREE, VG, and BOOM.
- Visit AMRN's SEC page to see the company's official filings. To visit the company's web site, go to www.amarincorp.com.
AMRN Stock Price Chart Interactive Chart >
AMRN Price/Volume Stats
| Current price | $4.60 | 52-week high | $26.12 |
| Prev. close | $4.60 | 52-week low | $3.36 |
| Day low | $4.54 | Volume | 4,258,500 |
| Day high | $4.67 | Avg. volume | 9,802,922 |
| 50-day MA | $4.59 | Dividend yield | N/A |
| 200-day MA | $7.28 | Market Cap | 1.80B |
Amarin Corporation plc, each representing one Ordinary Share (AMRN) Company Bio
Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States. The company was founded in 1989 and is based in Dublin, Ireland.
AMRN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $4.60 | $0 | -100% |
We started the process of determining a valid price forecast for Amarin Corp Plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Amarin Corp Plc ranked in the 0th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Amarin Corp Plc ended up being:
- The company's debt burden, as measured by earnings divided by interest payments, is -2.56 -- which is good for besting merely 14.5% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- The business' balance sheet suggests that 1% of the company's capital is sourced from debt; this is greater than only 6.2% of the free cash flow producing stocks we're observing.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -100% |
| 1% | -100% |
| 2% | -100% |
| 3% | -100% |
| 4% | -100% |
| 5% | -100% |
AGHC, ALC, ATRS, MOR, and PACB can be thought of as valuation peers to AMRN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...